REGISTRATION RIGHTS AGREEMENT

 
 
This Registration Rights Agreement (the “Agreement”) made as of the __ day of January, 2007 by and among BioLine Rx Ltd., with a business address at ▇▇ ▇▇▇▇▇▇ ▇▇., ▇.▇. ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇ (the “Company”) and shareholders of the Company listed on Schedule 1 hereto (the “Holders”);
 
 
WHEREAS the Board of Directors of the Company has determined that it is in the best interest of the Company that the Company shall grant the Holders certain rights as set forth herein; and
 
NOW THEREFORE, the parties, intending to be legally bound, hereby agree as follows:
 
1.            Registration.  The following provisions govern the registration of the Company's securities:
 
 
(a)          "Form S-3" means Form S-3 or Form F-3 under the United States Securities Act of 1933, as amended (the "Securities Act"), as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the Securities and Exchange Commission ("SEC") which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC;
 
(b)           
 
"IPO" shall mean the first registration statement for a public offering of securities of the Company, other than a registration statement relating to the sale of securities to employees of the Company pursuant to a stock option, stock purchase or similar plan;
 
 (c)         "Registrable Securities" means (1) Ordinary Shares now owned or hereafter acquired by the Holders, including all Ordinary Shares issuable with respect to Preferred Shares of the Company, and (2) any Ordinary Shares issued in respect of the shares described in clause (1) above (as a result of share splits, share dividends, reclassifications, recapitalizations or similar); provided, however, that Ordinary Shares that are Registrable Securities shall cease to be Registrable Securities upon (i) any sale thereof pursuant to a Registration Statement or Rule 144 under the Securities Act or (ii) any sale thereof in any manner to a person or entity which is not entitled to the rights provided by this Agreement;
 
(d)          "Register", "registered" and "registration" refer to a registration effected by filing a registration statement in compliance with the Securities Act and the declaration or ordering by the SEC of effectiveness of such registration statement, or the equivalent actions under the laws of any other jurisdiction;

 
 
 
 
 
(a)           If the Company at any time proposes to register any of its securities (other than in its IPO, a demand registration under Section 1.3, a registration relating to stock option plan(s) of the Company, or a registration on Form F-4/S-4 in connection with a merger, acquisition or other business combination, but including the first public offering of the Company’s shares in a U.S. market following an IPO), it shall give prompt written notice to all Holders of such intention, together with a list of jurisdictions in which the Company intends to attempt to qualify such securities under applicable state securities laws.  Upon the written request of any such Holder given within twenty (20) days after receipt of any such notice, the Company shall include in such registration all of the Registrable Securities indicated in such request, so as to permit the disposition of the shares so registered. The said “piggyback” or incidental right of the Holders under this Section, may be exercised an unlimited number of times.
 
(b)           Notwithstanding any other provision of this Section 1.2, if the managing underwriter, if any, advises the Company in writing that marketing factors require a limitation of the number of shares to be underwritten (an "Underwriters' Cutback"), then, there shall be excluded from such registration and underwriting, to the extent necessary to satisfy such limitation, first, securities of the Company not held by the Holders, to the extent necessary, and second, Registrable Securities, to the extent necessary (on a pro rata basis according to the respective holdings of the Holders of Registrable Securities at the time of such registration); provided however, that if the number of Registrable Securities to be registered by the Holders is limited by the underwriter, the securities to be sold for the account of the Company shall have priority over those of the Holders in each such registration and the number of Registrable Securities, if any, that may be included in the registration shall be in accordance with the above order and preference; further provided, however, that without the written consent of the Holders holding a majority of the Registrable Securities requested to be included in such registration the Registrable Securities held by the Holders shall not be reduced to less than twenty-five percent (25%) of the aggregate shares to be registered in such underwriting.
 
 
(a)           If the Company receives, at any time beginning six (6) months after the effective date of the IPO, from the Holders of a majority in interest of the Registrable Securities (calculated on an as converted basis) then outstanding, a request in writing that all or part of the Registrable Securities held by them having an aggregate value of at least $5,000,000 shall be registered for trading under the Securities Act, then, within seven (7) days after receipt of any such request, the Company shall give written notice of such request to the other Holders, and shall include in such registration all Registrable Securities held by all such Holders who wish to participate in such demand registration and provide the Company with written requests for inclusion therein within fifteen (15) days after the receipt of the Company's notice.  Thereupon, the Company shall use its best efforts to effect the registration of all Registrable Securities, as to which it has received requests for registration under the Securities Act.
 
(b)           Notwithstanding any other provision of Section 1.3(a), if the managing underwriter, if any, advises the Company in writing that marketing factors require an Underwriters Cutback, then there shall be excluded from such registration and underwriting, to the extent necessary to satisfy such limitation, first, securities of the Company not held by the Holders, to the extent necessary, and second, Registrable Securities, to the extent necessary (on a pro rata basis according to the respective holdings of the Holders of Registrable Securities at the time of such registration); provided however, that in any event all Registrable Securities must be included in such registration prior to any other shares of the Company.  The Holders shall not be entitled to request a registration under Section 1.3(a) if the Company shall furnish to the Holders a certificate signed by the CEO of the Company confirming that in the good faith judgment of the Board of Directors of the Company it would be seriously detrimental to the Company or its shareholders for such registration statement to be effected at such time, in which event the Company shall have the right to defer the filing of the registration statement for a period of no more than ninety (90) days after the receipt of the request of the Holders under Section 1.3(a); provided, however, the Company may not make more than one (1) such deferral in any twelve (12) month period.

 
 
 
 
(c)           In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 1.3(a):
 
(i)           after the Company has effected two (2) registrations pursuant to Section 1.3(a);

(ii)          during the period ending (A) six (6) months after the effective date of a registration subject to Section 1.3(a) hereof or (B) six (6) months after the effective date of any other registration statement pertaining to Ordinary Shares of the Company, or such shorter periods if such shorter periods are acceptable to the underwriters of such offering;

(iii)         in any jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act or applicable rules or regulations thereunder; or
 
(iv)         if such request does not cover shares representing a market value at the time of such request equal to a minimum of $5,000,000.
 
 
(a)           In the event the Company receives from any Holder a written request that the Company effect a registration on Form S-3, and any related qualification or compliance, the Company will within seven (7) days from receipt of any such request give written notice of the proposed registration, and any related qualification or compliance, to all other Holders, and include in such registration all Registrable Securities held by all such Holders, who wish to participate in such registration and provide the Company with written requests for inclusion therein within fifteen (15) days after the receipt of the Company's notice.  Thereupon, the Company shall use its best efforts to effect such registration of the Registrable Securities held by the Holders, and all such qualifications and compliances as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request.
 
(b)             In addition, the Company shall not be obligated to effect, or to take any action to effect, any registration qualification or compliance pursuant to Section 1.4(a):
 
(i)           if the Company has, within the twelve (12) month period preceding the date of such request, already effected two registrations on Form S-3 for the Holders pursuant to this Section 1.4;

(ii)          in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a general consent to service of process in effecting such registration, qualification or compliance;

(iii)         during the period ending 90 days after the effective date of any registration statement pertaining to Ordinary Shares of the Company (or such shorter period if such shorter period is acceptable to the underwriters of such offering);
 
(iv)         if such request does not cover shares representing a market value at the time of such request equal to a minimum of $1,000,000; or

 
 
 
 
(v)          if Form S-3 is not available for such offering by the Holders.
 
 
(a)           In the case of any underwritten registration effected pursuant to Section 1.3, a majority in interest of the Holders of the Registrable Shares (calculated on an as converted basis) that submitted the request for registration shall appoint an underwriter reasonably acceptable to the Company.
 
(b)           In the case of any registration initiated by the Company, the Company shall have the right to designate the managing underwriter in any underwritten offering.
 
 
 
1.7.1       The Company will indemnify and hold harmless, to the fullest extent permitted by law, any Holder (including its officers, directors, partners and legal counsel) and any underwriter for such Holder, and each person, if any, who controls the Holder or such underwriter, from and against any and all losses, damages, claims, liabilities, joint or several, costs and expenses (including any amounts paid in any settlement effected with the Company's consent) to which the Holder or any such underwriter or controlling person may become subject under applicable law or otherwise, insofar as such losses, damages, claims, liabilities (or actions or proceedings in respect thereof), costs or expenses arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in the registration statement or included in the prospectus, as amended or supplemented including any free writing prospectus, or (ii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances in which they are made, not misleading, (iii) any violation or alleged violation by the Company of the Securities Act, the Securities Exchange Act of 1934, as amended, any state securities law; or any rule or regulation promulgated under the Securities Act, Securities Exchange Act or any state security law; and the Company will reimburse the Holder, such underwriter and each such controlling person of the Holder or the underwriter, promptly upon demand, for any legal or any other expenses reasonably incurred by them in connection with investigating, preparing to defend or defending against or appearing as a third-party witness in connection with such loss, claim, damage, liability, action or proceeding; provided, however, that the Company will not be liable in any such case to the extent that any such loss, damage, liability, cost or expense arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished in writing by a  Holder, such underwriter or such controlling persons in writing specifically for inclusion therein; provided, further, that the indemnity agreement contained in this subsection 1.7.1 shall not apply to amounts paid in settlement of any such claim, loss, damage, liability or action if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the selling shareholder, the underwriter or any controlling person of the selling shareholder or the underwriter, and regardless of any sale in connection with such offering by the selling shareholder. Such indemnity shall survive the transfer of securities by a selling shareholder.

 
 
 
 
1.7.2       Each Holder participating in a registration hereunder will indemnify and hold harmless the Company, any underwriter for the Company, and each person, if any, who controls the Company or such underwriter, from and against any and all losses, damages, claims, liabilities, costs or expenses (including any amounts paid in any settlement effected with the selling shareholder's consent) to which the Company or any such controlling person and/or any such underwriter may become subject under applicable law or otherwise, insofar as such losses, damages, claims, liabilities (or actions or proceedings in respect thereof), costs or expenses arise out of or are based on (i) any untrue or alleged untrue statement of any material fact contained in the registration statement or included in the prospectus, as amended or supplemented, including any free writing prospectus or (ii) the omission or the alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances in which they were made, not misleading, and each such Holder will reimburse the Company, any underwriter and each such controlling person of the Company or any underwriter, promptly upon demand, for any reasonable legal or other expenses incurred by them in connection with investigating, preparing to defend or defending against or appearing as a third-party witness in connection with such loss, claim, damage, liability, action or proceeding; in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was so made in strict conformity with written information furnished by such  Holder specifically for inclusion therein. The foregoing indemnity agreement is subject to the condition that, insofar as it relates to any such untrue statement (or alleged untrue statement) or omission (or alleged omission) made in the preliminary prospectus but eliminated or remedied in the amended prospectus at the time the registration statement becomes effective or in the Final Prospectus, such indemnity agreement shall not inure to the benefit of (i) the Company and (ii) any underwriter, if a copy of the Final Prospectus was not furnished to the person or entity asserting the loss, liability, claim or damage at or prior to the time such furnishing is required by the Securities Act; provided, further, that this indemnity shall not be deemed to relieve any underwriter of any of its due diligence obligations; provided, further, that the indemnity agreement contained in this subsection 1.7.2 shall not apply to amounts paid in settlement of any such claim, loss, damage, liability or action if such settlement is effected without the consent of the Holders, as the case may be, which consent shall not be unreasonably withheld.  In no event shall the liability of a Holder exceed the net proceeds from the offering received by such Holder.
 
1.7.3       Promptly after receipt by an indemnified party pursuant to the provisions of Sections 1.7.1 or 1.7.2 of notice of the commencement of any action involving the subject matter of the foregoing indemnity provisions, such indemnified party will, if a claim thereof is to be made against the indemnifying party pursuant to the provisions of said Section 1.7.1 or 1.7.2, promptly notify the indemnifying party of the commencement thereof; but the omission to notify the indemnifying party will not relieve it from any liability which it may have to any indemnified party otherwise than hereunder.  In case such action is brought against any indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party shall have the right to participate in, and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; provided, however, that if the defendants in any action include both the indemnified party and the indemnifying party and there is a conflict of interests which would prevent counsel for the indemnifying party from also representing the indemnified party, the indemnified party or parties shall have the right to select one separate counsel to participate in the defense of such action on behalf of such indemnified party or parties. After notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party pursuant to the provisions of said Sections 1.7.1 or 1.7.2 for any legal or other expense subsequently incurred by such indemnified party in connection with the defense thereof, unless (i) the indemnified party shall have employed counsel in accordance with the provision of the preceding sentence, (ii) the indemnifying party shall not have employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after the notice of the commencement of the action and within fifteen (15) days after written notice of the indemnified party's intention to employ separate counsel pursuant to the previous sentence, or (iii) the indemnifying party has authorized the employment of counsel for the indemnified party at the expense of the indemnifying party.  No indemnifying party will consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation.

 
 
 
 
1.7.4       If recovery is not available under the foregoing indemnification provisions, for any reason other than as specified therein, the parties entitled to indemnification by the terms thereof shall be entitled to contribution to liabilities and expenses as more fully set forth in an underwriting agreement to be executed in connection with such registration. In determining the amount of contribution to which the respective parties are entitled, there shall be considered the parties' relative knowledge and access to information concerning the matter with respect to which the claim was asserted, the opportunity to correct and prevent any statement or omission, and any other equitable considerations appropriate under the circumstances. In no event shall the contribution obligation of a Holder exceed the net proceeds from the offering received by such Holder.
 
 
1.8.1       Prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to nine months or, if sooner, until the distribution contemplated in the Registration Statement has been completed;
 
1.8.2       Prepare and file with the SEC such amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such registration statement;
 
1.8.3       Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents, including any free writing prospectus as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them;
 
1.8.4       In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering.  Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement;
 
1.8.5       Notify each holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing;
 
1.8.6       Cause all Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed;

 
 
 
 
1.8.7       Provide a transfer agent and registrar for all Registrable Securities registered pursuant hereunder and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;
 
1.8.8       Furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, if such securities are being sold through underwriters, or, if such securities are not being sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the  Holders requesting registration of Registrable Securities, and (ii) a letter dated such date, from the independent certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities;
 
 
1.10        Lock-Up and Other Requests by the Underwriter.  Each Holder hereby agrees that such Holder shall not sell or otherwise transfer or dispose of any Registrable Securities of the Company held by such Holder (other than those included in the registration) for a period specified by the representative of the underwriters of Ordinary Shares (or other securities) of the Company not to exceed one hundred eighty (180) days following the effective date of the IPO, and provided that each of the senior officers of the Company (i.e. CEO and CFO) and holders of at least one percent (1%) of the Company’s issued and outstanding shares enters in an identical undertaking. Each Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which are consistent with the foregoing or which are necessary to give further effect thereto. The Company may impose stop-transfer instructions with respect to the shares of Ordinary Shares (or other securities) subject to the foregoing restriction until the end of said one hundred eighty (180) day period;
 
 
(a)           make and keep public information available, as those terms are understood and defined in SEC Rule 144 or any similar or analogous rule promulgated under the Securities Act, at all times after the effective date of the first registration filed by the Company for an offering of its securities to the general public;
 
(b)           file with the SEC, in a timely manner, all reports and other documents required of the Company under the Exchange Act; and

 
 
 
 
(c)           so long as a Holder owns any Registrable Securities, furnish to such Holder forthwith upon request: a written statement by the Company as to its compliance with the reporting requirements of said Rule 144 of the Securities Act, and of the Exchange Act (at any time after it has become subject to such reporting requirements); a copy of the most recent annual or quarterly report of the Company; and such other reports and documents as a Holder may reasonably request in availing itself of any rule or regulation of the SEC allowing it to sell any such securities without registration;
 
 
 
 
2.1           Further Assurances.  Each of the parties hereto shall perform such further acts and execute such further documents as may reasonably be necessary to carry out and give full effect to the provisions of this Agreement and the intentions of the parties as reflected thereby.
 
 
 
 
(a)           This Agreement constitutes the full and entire understanding and agreement between the parties, and supersedes any agreement and understanding between any of the parties, with regard to the subject matters hereof.  (b)Any term of this Agreement (as amended) may be amended and the observance of any term hereof may be waived (either prospectively or retroactively and either generally or in a particular instance) only with the written consent of: (i) the Company, and (ii) a majority of interest of the holders of Registrable Securities (calculated on an as converted basis); provided that (x) should such waiver or amendment adversely affect the rights or privileges granted hereunder to the particular Holder or group of Holders, in a manner which discriminates such Holder/s against other Holders (a “Discriminated Class”), such waiver or amendment shall be subject to the written approval of the Holder/s who are the owners of record of a majority of the outstanding shares of such Discriminated Class, and (y) any right or limitation provided for the express benefit of a specifically named party may not be amended or waived without the consent of such party. Any amendment or waiver effected in accordance with this Section 2.4 shall be binding upon the Company, the Holders, and each of their respective successors and assigns.

 
 
 
 
 
2.5.1       All notices and other communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given: (i) in the case of hand delivery to the address shown below, on the next Business Day after delivery; (ii) in the case of delivery by an internationally recognized overnight courier to the address set forth below, freight prepaid, on the next Business Day after delivery; (iii) in the case of a notice sent by facsimile transmission or email to the number, and addressed as, set forth below, on the next Business Day after delivery, if facsimile transmission or email is confirmed; (iv) in the case of a notice sent by email to any of the email addresses set forth in  Schedule 1 hereto, on the date of written acknowledgment of receipt of such email by the receiving party. A “Business Day” means a day on which the banks are open for business in the country of receipt of any notice.
 
2.5.2       In the event that notices are given pursuant to one of the methods listed in subsections 2.5.1 (i) to (iii) above, a copy of the notice shall also be sent by email to such address set forth in Schedule 1.
 
2.5.3       A party may change or supplement the contact details for service of any notice pursuant to this Agreement, or designate additional addresses, facsimile numbers and email addresses for the purposes of this Section 2.5 by giving the other party written notice of the new contact details in the manner set forth above.
 
if to the Holders:
to the addresses set forth in Schedule 1;
   
If to the Company:
To the address set forth in the Preamble
   
With a copy to:
▇▇▇▇▇ ▇▇▇▇▇ & Co.
 
▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇
 
▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇▇
 
Attn.: Adv. ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
 
Tel: ▇▇▇-▇-▇▇▇-▇▇▇▇
 
Fax: ▇▇▇-▇-▇▇▇-▇▇▇▇
 
 
 
 

 
 
 
 
[REMAINDER OF PAGE INTENTIONALLY BLANK]

 
 
 

IN WITNESS WHEREOF, the parties have signed this Investors Rights Agreement as of the date first hereinabove set forth.
 
 BIOLINE RX LTD.
  SHAREHOLDERS – SEE SEPARATE
  SIGNATURE PAGE
 by:
/s/ ▇▇▇▇ ▇▇▇▇▇▇▇
  
 name:
▇▇▇▇ ▇▇▇▇▇▇▇
  
 title:
Vice President, Finance and
  
 Corporate Development
  
 
 

IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.

Jerusalem Development Authority
  
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇
Print or Type Name of Shareholder
  
Signature
     
   
C.E.O.
   
 (Title, if applicable)
     
Typed or printed name and address of Shareholder:
  
Fax Number:       972-2-6250875
     
   
Telephone:          ▇▇▇-▇-▇▇▇▇▇▇▇
     
   
Email:                 ▇▇▇▇@▇▇▇.▇▇▇.▇▇
 
 
 
 


IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.
 
Typed or printed name and address of Shareholder:
      
       
/s/ ▇▇▇▇ ▇▇▇▇ 
    
Pitango Venture Capital Fund III (Israeli Sub), L.P.
    
Pitango Venture Capital Fund III (Israeli Sub) Non-Q L.P.
    
Pitango Venture Capital Fund III (Israeli Investors), L.P.      
Pitango Principals Fund III (Israel), L.P.      
Pitango Venture Capital Fund III Trusts 2000 Ltd.      
 
 
 
 


IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.

Hadasit
  
/s/ ▇▇▇▇ ▇▇▇▇▇▇▇▇
Print or Type Name of Shareholder
  
Signature
     
   
C.E.O.
   
 (Title, if applicable)
     
Typed or printed name and address of Shareholder:
  
Fax Number:
     
   
Telephone:
     
   
Email:
  
 
 
 


IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.
 
Giza GE Venture Fund III, LLC
    
Giza Alpinvest Venture Fund III, LLC
  
/s/
▇▇▇▇ ▇▇▇▇▇, Managing Director
Giza Venture Fund III Limited Partnership
  
 
 
Giza Gmulot Venture Fund III Limited Partnership
  
/s/ 
▇▇▇ ▇▇▇▇▇▇▇▇▇, Managing Director
Giza Executive Venture Fund III, LLC
  
Signature
Giza Venture Fund IV, LP
    
Giza Venture Fund IV (TW) L.P.
    
Giza Venture Fund IV (Jersey) LP
    
Giza Venture Fund IV (Israel) Limited Partnership
    
     
Print or Type Name of Shareholder
    
 
 
 
 

Registration Rights Agreement - Signature Page

IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.
 
SVE Star Ventures Enterprises GmbH & Co. No. IX KG
  
SVM Star Ventures Managementgesellschaft mbH Nr.
  
3 & Co. Beteiligungs KG Nr. 4
  
   
By: SVM Star Ventures Managementgesellschaft mbH Nr. 3
  
Title: Managing Partner
  
/s/ ▇▇▇▇ ▇▇▇▇▇
  
By: ▇▇. ▇▇▇▇ ▇▇▇▇▇
  
Title: Managing Director
  
   
Star Management of Investments No II (2000), L.P.
  
By: SVM STAR Venture Capital Management Ltd.
  
Title: Managing Partner
  
/s/ ▇▇▇▇ ▇▇▇▇▇
  
By: ▇▇. ▇▇▇▇ ▇▇▇▇▇
  
Title: Director
  


 
 
 

Registration Rights Agreement - Signature Page

IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.
 
▇▇▇▇▇▇ ▇▇▇▇▇▇▇
  
/s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇
Print or Type Name of Shareholder
  
Signature
     
   
(Title, if applicable)
     
Typed or printed name and address of Shareholder:
  
Fax Number:            ▇▇▇-▇-▇▇▇▇▇▇▇
     
▇▇▇▇▇▇ ▇▇▇▇▇▇▇
  
Telephone:               ▇▇▇-▇-▇▇▇▇▇▇▇
c/o RAD Group
  
 
▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇,
  
Email:                      ▇▇▇▇▇▇_▇@▇▇▇.▇▇▇
▇▇▇ ▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇
  
 
     
 
 
 
 

Registration Rights Agreement - Signature Page

IN WITNESS WHEREOF, by executing this Signature Page, the undersigned has read, understood and acknowledged the representations and covenants in the Registration Rights Agreement (the “RRA”) by and between BioLine Rx Ltd. (the “Company”) and its shareholders.  Upon receipt by the Company of this Signature Page and execution by the Company of its counterpart signature page, the undersigned shall become a party to the RRA, and hereby authorizes this signature page to be attached to a counterpart of the RRA executed by the Company.
 
Pan Atlantic Investments Limited
/s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
 
▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
 
Managing Director
   
▇▇▇▇▇▇ Building, 2nd Floor
Fax Number:         (▇▇▇) ▇▇▇-▇▇▇▇
▇▇▇▇▇▇ Street
  
Bridgetown
Telephone:            (▇▇▇) ▇▇▇-▇▇▇▇
Barbados West Indies 11000
  
 
Email:                   ▇▇▇▇▇▇▇▇▇@▇▇▇▇.▇▇
   
 
 
 
 

Document Metadata

Filed: July 1st, 2011

Related content

AI Assistant